BBOT vs RCUS
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. RCUS: A clinical-stage biotech developing first-in-class and best-in-class small molecules and antibodies for cancer immunotherapy, with lead HIF-2α inhibitor in late-stage trials.
Side-by-side fundamentals
| Metric | BBOT | RCUS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.90 | $29.97 | |
| Market cap as of 2026-07-23 | $701M | $3.7B | |
| P/E as of 2026-07-23 | 148.50 | n/a | |
| Net margin as of 2026-07-23 | n/a | -156.4% | |
| Operating margin as of 2026-07-23 | n/a | -168.6% | |
| ROE as of 2026-07-23 | +2.5% | -69.0% | BBOT higher |
| ROA as of 2026-07-23 | +2.4% | -35.3% | BBOT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.19 | BBOT lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -15.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.6% | |
| Beta as of 2026-07-23 | 0.82 | 0.81 | |
| 1-year return as of 2026-07-22 close | -18.7% | +218.4% | RCUS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.